RBC Capital notes that the clinicaltrials.gov listing for an open-label study of Teva‘s (TEVA) Austedo in cerebral palsy was just updated to indicate that it has been terminated as the main phase 3 study for that drug in cerebral palsy had failed. The analyst also points out that Neurocrine (NBIX), as part of its life cycle strategy, has been conducting phase 3 studies for Ingrezza in additional indications beyond TD and Huntington’s, namely schizophrenia and cerebral palsy, and said that Austedo, which is on the market for TD and Huntington’s, "has a nearly identical mechanism to Ingrezza." Teva’s study failure could increase the risk for Neurocrine’s cerebral palsy trial and may add incremental risk to the CP indication for Neurocrine, though the latter’s recent trial adjustments "could still preserve some potential" for it to succeed in phase 3, said the firm, which maintains a Sector Perform rating and $110 price target on Neurocrine shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine announces results of published study on tardive dyskinesia
- Neurocrine to present data on Ingrezza capsule dissolution performance
- ‘2023 Rally Was a Bull Trap,’ Says Morgan Stanley. But These Stocks Still Have Upside
- Neurocrine upgraded to Outperform at Evercore with stock 25% off highs
- Neurocrine upgraded to Outperform from In Line at Evercore ISI
Questions or Comments about the article? Write to editor@tipranks.com